AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CG Oncology Soars 36.34% on Bladder Cancer Drug Data
Generated by AI AgentAinvest Movers Radar
Monday, Apr 28, 2025 7:13 am ET1min read
On April 28, 2025, CG Oncology's stock surged by 36.34% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
CG Oncology recently announced impressive durability data from its BOND-003 Cohort C, showcasing the effectiveness of Cretostimogene Grenadenorepvec in treating bladder cancer. The study revealed a median duration of response of 28 months, with 97.3% of patients remaining free from progression to muscle-invasive bladder cancer at the 24-month mark. This data underscores the potential of Cretostimogene Grenadenorepvec as a groundbreaking treatment option, contributing to the stock's positive momentum.
Additionally, the company reported a 75.5% complete response rate at any time, with 34 confirmed complete responses at 24 months and 9 patients pending their 24-month assessment. These findings further solidify the therapeutic benefits of Cretostimogene Grenadenorepvec, reinforcing investor confidence in CG Oncology's innovative approach to cancer treatment.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Dynavax (DVAX) Shares Plunge 1.70% Amid Regulatory and Legal Risks in Sanofi Deal
Dec.24 2025
Intuitive Machines Stock Plunges 12.04% on CEO Share Sale Q3 Loss Acquisition Risks
Dec.24 2025
Repare Therapeutics Dives 2.25% to 12-Month Low Amid Strategic Uncertainty *Key drivers: Pending XenoTherapeutics bid, Gilead asset sale reshape investor sentiment*
Dec.24 2025
Reviva Pharmaceuticals (RVPH) Plunge 55.93% as FDA Demands Additional Trial for Schizophrenia Drug
Dec.24 2025
Fermi Shares Plunge 7.21% to Monthly Low on AICA Termination, Legal Scrutiny
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet